Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
06 2020
Historique:
received: 10 12 2019
revised: 21 02 2020
accepted: 05 03 2020
pubmed: 1 4 2020
medline: 15 4 2021
entrez: 1 4 2020
Statut: ppublish

Résumé

The quality of radiation therapy has been shown to significantly influence the outcomes for head and neck squamous cell carcinoma (HNSCC) patients. The results of dosimetric studies suggest that intensity-modulated proton therapy (IMPT) could be of added value for HNSCC by being more effective than intensity-modulated (photon) radiation therapy (IMRT) for reducing side effects of radiation therapy. However, the physical properties of protons make IMPT more sensitive than photons to planning uncertainties. This could potentially have a negative effect on the quality of IMPT planning and delivery. For this review, the three French proton therapy centers collaborated to evaluate the differences between IMRT and IMPT. The review explored the effects of these uncertainties and their management for developing a robust and optimized IMPT treatment delivery plan to achieve clinical outcomes that are superior to those for IMRT. We also provide practical suggestions for the management of HNSCC carcinoma with IMPT. Because metallic dental implants can increase range uncertainties (3-10%), patient preparation for IMPT may require more systematic removal of in-field alien material than is done for IMRT. Multi-energy CT may be an alternative to calculate more accurately the dose distribution. The practical aspects that we describe are essential to guarantee optimal quality in radiation therapy in both model-based and randomized clinical trials.

Identifiants

pubmed: 32224315
pii: S0167-8140(20)30115-8
doi: 10.1016/j.radonc.2020.03.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

30-39

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Arnaud Beddok (A)

Institut Curie, Department of Radiation Oncology, Paris, France.

Anthony Vela (A)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France.

Valentin Calugaru (V)

Institut Curie, Department of Radiation Oncology, Paris, France.

Thomas Tessonnier (T)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France.

Jiri Kubes (J)

Proton Therapy Center Czech., Prague, Czech Republic.

Pauline Dutheil (P)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France.

Anais Gerard (A)

Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France.

Marie Vidal (M)

Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France.

Farid Goudjil (F)

Institut Curie, Department of Radiation Oncology, Paris, France.

Carmen Florescu (C)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France.

Emmanuel Kammerer (E)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France.

Karen Benezery (K)

Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France.

Joel Herault (J)

Centre Antoine Lacassagne, Department of Radiation Oncology, Nice, France.

Philip Poortmans (P)

Institut Curie, Department of Radiation Oncology, Paris, France; Paris Sciences & Lettres - PSL University, Paris, France.

Jean Bourhis (J)

Centre Hospitalier Universitaire Vaudois, Department of Radiation Oncology, Lausanne, Switzerland.

Juliette Thariat (J)

Centre François Baclesse, Department of Radiation Oncology, Caen, Unicaen - Normandie Université, France; ARCHADE (Advanced Resource Center for Hadrontherapy in Europe), Caen, France; Laboratoire de physique corpusculaire, IN2P3/ENSICAEN - UMR6534 - Unicaen - Normandie Universite, France. Electronic address: jthariat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH